COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00211445
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : September 28, 2007
Information provided by:
Manhattan Eye, Ear & Throat Hospital

Brief Summary:
Central serous choroidal (CSC) retinopathy is a disease of the macula characterized by exudation of fluid under the retina localized to the posterior pole as well as loss of vision. The etiology is unknown, but according to the studies this condition is more common in young males and is associated with type A personality. Clinically, CSC is characterized by serous retinal detachment and area of leakage of in the subretinal space. The standard of care for acute CSC is observation for a period of up to 3 months. If there is no complete resolution of the retinal detachment by 3 months, there is an indication for focal laser photocoagulation therapy of the area of leakage. This treatment is usually effective in stopping leakage of fluid under the retina and causing resolution of detachment. However, laser photocoagulation therapy is not beneficial in the treatment of chronic CSC because there is not a single easily identifiable point of leakage but rather diffuse disease of RPE thus rendering laser treatment ineffective.The purpose of this medical research study is to evaluate Verteporfin therapy as an approach which may benefit patients with CSC, based on observations in exudative type of AMD patients treated with Photodynamic Therapy using Verteporfin.

Condition or disease Intervention/treatment Phase
Chronic Central Serous Chorioretinopathy Procedure: Photodynamic Therapy with Verteporfin Drug: verteporfin Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : July 2002
Actual Study Completion Date : January 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Verteporfin

Primary Outcome Measures :
  1. mean change in VA (ETDRS) from baseline to 24 months [ Time Frame: 24 months ]
  2. investigate the potential of photodynamic therapy using verteporpin in chronic central serous chorioretinopathy [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. mean change of VA(ETDRS), OCT, FA from baseline to 24 months [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Evidence of chronic central serous chorioretinopathy and clinical/angiographic findings typical of the disease of greater than 6 months duration.Chronic central serous chorioretinopathy could be defined on the basis of two factors: a) persistence of the detachment for more than 6 months and b) chronic recurrent acute detachments with widespread decompensation of the retinal pigment epithelium.
  2. VA 20/40 and 20/320 Study Eye on the ETDRS visual acuity chart.
  3. VA 20/800 or better Fellow Eye on the ETDRS visual acuity chart.

Exclusion Criteria:

  1. Patient with tears in retinal pigment epithelium.
  2. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
  3. Patients who have undergone intraocular surgery within last 2 months or capsulotomy within last month in study eye.
  4. Patient participating in any other investigational drug study.
  5. Inability to obtain photographs to document CNV (including difficulty with venous access).
  6. Patient with significant liver disease or uremia.
  7. Patient with known adverse reaction to indocyanine green or iodine.
  8. Patient is pregnant or nursing
  9. Age less than 18 years old

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00211445

Layout table for location information
United States, New York
Manhattan Eye, Ear & Throat Hospital
New York, New York, United States, 10021
Sponsors and Collaborators
Manhattan Eye, Ear & Throat Hospital
Layout table for investigator information
Principal Investigator: Jason S. Slakter, MD Manhattan Eye, Ear & Throat Hospital
Layout table for additonal information Identifier: NCT00211445    
Other Study ID Numbers: PDT for CSC
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: September 28, 2007
Last Verified: September 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases
Photosensitizing Agents
Dermatologic Agents